On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

Study compared telehealth with in-person meeting as a modality for effective delivery of early palliative care.

Medicaid expansion was associated with earlier diagnosis, more timely initiation of guideline-concordant care, and better ...

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Mersana Therapeutics (MRSN – Research Report). The associated ...

ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met ...

FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...

Survival in NSCLC improved with guideline-concordant care in lung cancer, and several factors can be addressed to reach more ...

But you might look at its pipeline and conclude that the biotech is a one-trick pony, as its lack of diversification is acute ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.